Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Employees - 48000,
CEO - Mr. Michael F. Mahoney,
Sector - Healthcare,
Country - US,
Market Cap - 131.53B
Altman ZScore(max is 10): 5.39, Piotroski Score(max is 10): 7, Working Capital: $2851000000, Total Assets: $38078000000, Retained Earnings: $2107000000, EBIT: 2499000000, Total Liabilities: $17122000000, Revenue: $15910000000
AryaFin Target Price - $28.06 - Current Price $88.95 - Analyst Target Price $100.96
Ticker | BSX |
Index | S&P 500 |
Curent Price | 88.95 |
Change | 0.33% |
Market Cap | 131.53B |
Average Volume | 5.85M |
Income | 1.79B |
Sales | 15.91B |
Book Value/Share | 14.05 |
Cash/Share | 1.74 |
Dividend Est | - |
Dividend TTM | - |
Dividend Ex-Date | - |
Employees | 48000 |
Moving Avg 20days | -1.15% |
Moving Avg 50days | 0.81% |
Moving Avg 200days | 12.89% |
Shares Outstanding | 1.47B |
Earnings Date | Oct 23 BMO |
Inst. Ownership | 91.35% |
Price/Earnings | 73.57 |
Forwad P/E | 31.78 |
PE Growth | 5.18 |
Price/Sales | 8.27 |
Price/Book | 6.33 |
Price/Cash | 51.14 |
Price/FCF | 61.00 |
Quick Ratio | 1.02 |
Current Ratio | 1.48 |
Debt/Equity | 0.54 |
Return on Assets | 4.97% |
Return on Equity | 9.05% |
Return on Investment | 5.91% |
Gross Margin | 62.41% |
Ops Margin | 16.49% |
Profit Margin | 11.26% |
RSI | 48.18 |
BETA(β) | 0.80 |
From 52week Low | 61.87% |
From 52week High | -3.24% |
EPS | 1.21 |
EPS next Year | 2.80 |
EPS next Qtr | 0.66 |
EPS this Year | 20.06% |
EPS next 5 Year | 14.20% |
EPS past 5 Year | -2.05% |
Sales past 5 Year | 8.10% |
EPS Y/Y | 48.36% |
Sales Y/Y | 15.65% |
EPS Q/Q | -7.91% |
Sales Q/Q | 19.34% |
Sales Surprise | 4.16% |
EPS Surprise | 7.09% |
ATR(14) | 1.62 |
Perf Week | -1.29% |
Perf Month | -1.35% |
Perf Quarter | 5.89% |
Perf Year | 61.79% |
Perf YTD | 53.87% |
Target Price | 100.96 |
AryaFin Engine© - An AI FinTech Venture - 2024 Disclaimer